What is IPH6401/SAR445514?
IPH6401/SAR445514 (SAR’514) is a trifunctional anti-BCMA NKp46/CD16 NK cell engager using Sanofi’s proprietary CROSSODILE® multi-functional platform, which comprises the Cross-Over-Dual-Variable-Domain (CODV) format.
Mechanism of action
It induces a dual targeting of the NK activating receptors, NKp46 and CD16, for an optimized NK cell activation, based on Innate’s ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform.
- Multiple myeloma is characterized by a proliferation of plasma cells in the bone marrow that synthesize monoclonal Ig and infiltrate and destroy adjacent bone tissue.
- AL amyloidosis induces a clonal disorder of B cells characterized by aggregation and deposition of insoluble amyloid fibrils secondary to misfolding of monoclonal immunoglobulin light chains. It generally presents as systemic AL amyloidosis affecting one or more parenchymal organs, and more rarely as localized amyloidosis with generally nodular deposits confined to a single organ and/or system.
| IPH6401/ SAR445514 BCMA Collaboration with Sanofi | Clinical trial, in patients with relapsed/refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA), sponsored by Sanofi.
| ||
| Preclinical | Phase 1/2 | Phase 3 | |
The Company has a research collaboration and licensing agreement with Sanofi to apply Innate’s proprietary platform to the development of innovative multi-specific antibody formats engaging NK cells through the activating receptors NKp46 and CD16 to kill tumor cells now called the ANKET platform.
Under the terms of the license agreement, Sanofi will be responsible for the development, manufacturing and commercialization of products resulting from the research collaboration. Innate Pharma will be eligible to up to €400m in development and commercial milestone payments as well as royalties on net sales. A new licensing agreement was signed with Sanofi in 2022, to include new drug candidates in the collaboration, bringing the total value of the agreement to 1.75 billion euros.
Publications, posters and presentations